The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

By T. Bjornsson, J. Callaghan, H. Einolf, V. Fischer, Lawrence L. Gan, S. Grimm, J. Kao, S. P. King, G. Miwa, L. Ni and 12 more. Drug Metabolism And Disposition, 2003

784 citations recorded by the source corpus.

Subfields: Oncology, Pediatrics, Perinatology and Child Health, Pharmacology

View Paper: https://www.semanticscholar.org/paper/b9a2fa8e58a633850280cf7bf5c3bbba574b881d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. R. Hyland
2. J. A. Williams
3. Dennis A. Smith
4. Barry C. Jones
5. Susan I. Hurst

Citations in the corpus

• DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS (2004, background): “The conduct of these studies in early drug discovery (Williams et al., 2003) and for definitive purposes (Bjornsson et al., 2003) has been previously described.”